Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1

被引:64
|
作者
Cole, J. C. [1 ]
Lin, P. [1 ]
Rupnow, M. F. T. [2 ]
机构
[1] QualityMetric, Lincoln, RI 02865 USA
[2] Ortho McNeil Janssen Sci Affairs LLC, Titusville, NJ USA
关键词
MSQ; migraine; prophylaxis; MID; MCID; HEALTH-STATUS MEASURES; ITEM RESPONSE THEORY; INTRAINDIVIDUAL CHANGES; RELIABILITY; IMPACT; RESPONSIVENESS; PREVENTION; TOPIRAMATE; VALIDITY; SCORE;
D O I
10.1111/j.1468-2982.2009.01852.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To propose minimal important differences (MID) for the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1). To our knowledge (to date), no published MID values exist for the MSQ v2.1 in any population. Analyses were performed on data from two pivotal clinical trials of topiramate for migraine prevention (n = 916), as well as from the QualityMetric National Headache Survey (n = 1016). Analyses included both distribution- and anchor-based MID techniques as well as group- and individual-level MID values. Group-level anchor-based MID values ranged from 3.2 [Role Restrictive domain (RR)] to 7.5 [Emotional Functioning domain (EF)], setting the minimum level of appropriate MID (which can also aid with power analysis). Individual-level distribution-based MID values resulted in highly similar estimates from two large databases: median MID of 8.5 for RR, 9.2 for Role Preventive (RP) and 12.0 for EF. Finally, individual-level anchor-based MID values ranged from 5.0 (RR and RP domains) to 10.6 (EF). For group-level purposes of calculating power for future studies, an MID of 3.2, 4.6 and 7.5 for RR, RP and EF is recommended. For within-group analyses for analysing clinical trial efficacy of each patient's change with responder analyses, 5 points is necessary for RR. For RP and EF, ranges are recommended: 5.0 to 7.9 for RP and 8.0 to 10.6 for EF. These latter two domains tend to have more error in the MID, and thus a sensitivity analysis with both ends of the range should be used to confirm significant differences in responder analyses.
引用
收藏
页码:1180 / 1187
页数:8
相关论文
共 50 条
  • [11] Validation of the Korean Migraine-Specific Quality of Life Questionnaire Version 2.1 in Episodic and Chronic Migraine
    Seo, Jong-Geun
    Park, Sung-Pa
    JOURNAL OF ORAL & FACIAL PAIN AND HEADACHE, 2017, 31 (03) : 251 - 256
  • [12] Validity, reliability, and sensitivity to change of the Thai version of the Migraine-Specific Quality of Life Questionnaire version 2.1
    Asawavichienjinda, Thanin
    Vorasayan, Pongpat
    Noiwattanakul, Jirawadee
    Phanthumchinda, Kammant
    ASIAN BIOMEDICINE, 2017, 11 (04) : 331 - 342
  • [13] Migraine-Specific Quality of Life Questionnaire Chinese version 2.1 (MSQv2.1-C): psychometric evaluation in patients with migraine
    Hao-Yuan Chang
    Mark P. Jensen
    Chih-Chao Yang
    Yeur-Hur Lai
    Health and Quality of Life Outcomes, 17
  • [14] Validating the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) in Italian inpatients with chronic migraine with a history of medication overuse
    Alberto Raggi
    Ambra Mara Giovannetti
    Silvia Schiavolin
    Matilde Leonardi
    Gennaro Bussone
    Licia Grazzi
    Susanna Usai
    Marcella Curone
    Paola Di Fiore
    Domenico D’Amico
    Quality of Life Research, 2014, 23 : 1273 - 1277
  • [15] Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study
    Shibata, Mamoru
    Nakamura, Tomomi
    Ozeki, Akichika
    Ueda, Kaname
    Nichols, Russell M.
    JOURNAL OF PAIN RESEARCH, 2020, 13 : 3531 - 3538
  • [16] Validating the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) in Italian inpatients with chronic migraine with a history of medication overuse
    Raggi, Alberto
    Giovannetti, Ambra Mara
    Schiavolin, Silvia
    Leonardi, Matilde
    Bussone, Gennaro
    Grazzi, Licia
    Usai, Susanna
    Curone, Marcella
    Di Fiore, Paola
    D'Amico, Domenico
    QUALITY OF LIFE RESEARCH, 2014, 23 (04) : 1273 - 1277
  • [17] MSQ: Migraine-Specific Quality-of-Life Questionnaire - Further investigation of the factor structure
    Jhingran, P
    Davis, SM
    LaVange, LM
    Miller, DW
    Helms, RW
    PHARMACOECONOMICS, 1998, 13 (06) : 707 - 717
  • [18] Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients With Episodic Migraine by Galcanezumab Treatment: CGAN Japan Phase 2 Study
    Shibata, M.
    Nakamura, T.
    Kuga, A.
    Ozeki, A.
    Nichols, R. M.
    HEADACHE, 2020, 60 : 114 - 114
  • [19] The Psychometric Properties of the Persian Migraine-Specific Quality of Life Questionnaire Version 2.1 in Episodic and Chronic Migraines
    Zandifar, Alireza
    Masjedi, Samaneh Sadat
    Haghdoost, Faraidoon
    Asgari, Fatemeh
    Manouchehri, Navid
    Banihashemi, Mahboobeh
    Najafi, Mohammad Reza
    Ghorbani, Abbas
    Zolfaghari, Behzad
    Gholamrezaei, Ali
    Shaygannejad, Vahid
    Saadatnia, Mohammad
    SCIENTIFIC WORLD JOURNAL, 2013,
  • [20] Content validity of the Migraine-Specific Quality of Life Questionnaire version 2.1 electronic patient-reported outcome
    Speck, Rebecca M.
    Shalhoub, Huda
    Ayer, David W.
    Ford, Janet H.
    Wyrwich, Kathleen W.
    Bush, Elizabeth N.
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2019, 3 (01)